RAPA-201 Rapamycin Resistant T Cells is named as a drug or biological intervention in 2 clinical trials in our USA trial register, 1 of which is recruiting. The lead sponsor is Rapa Therapeutics LLC. Registered phases: Phase 2 and Phase 1/2. Conditions studied include Malignant Melanoma With Metastasis; Malignant Melanoma; Malignant Melanoma Stage IIIc.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT05144698 | RAPA-201 Therapy of Solid Tumors (ClinicalTrials.gov ↗) Solid Tumor, Small Cell and Non-small Cell Lung Cancer, Head and Neck Cancer |
Phase 1/2 | Recruiting |
| NCT06708455 | Phase 2b of RAPA-201 Cell Therapy in Post-PD-(L)-1 Melanoma Malignant Melanoma With Metastasis, Malignant Melanoma, Malignant Melanoma Stage IIIc |
Phase 2 | Not yet open |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Malignant Melanoma With Metastasis | 1 |
| Malignant Melanoma | 1 |
| Malignant Melanoma Stage IIIc | 1 |
| Malignant Melanoma Stage IV | 1 |
| Solid Tumor | 1 |
| Small Cell and Non-small Cell Lung Cancer | 1 |
| Head and Neck Cancer | 1 |
| Squamous Cell Carcinoma of Oral Cavity | 1 |
| Lead sponsor | Trials |
|---|---|
| Rapa Therapeutics LLC | 2 |
| Register | RAPA-201 Rapamycin Resistant T Cells trials |
|---|---|
| Clinical trials in USA | 2 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how RAPA-201 Rapamycin Resistant T Cells works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists RAPA-201 Rapamycin Resistant T Cells (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.